A biopsy is a medical test commonly performed by a surgeon, an interventional radiologist, or an interventional cardiologist. The process involves the extraction of sample cells or tissues for examination to determine the presence or extent of a disease. The tissue is then fixed, dehydrated, embedded, sectioned, stained and mounted before it is generally examined under a microscope by a pathologist; it may also be analyzed chemically. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. An incisional biopsy or core biopsy samples a portion of the abnormal tissue without attempting to remove the entire lesion or tumor. When a sample of tissue or fluid is removed with a needle in such a way that cells are removed without preserving the histological architecture of the tissue cells, the procedure is called a needle aspiration biopsy. Biopsies are most commonly performed for insight into possible cancerous or inflammatory conditions.
Joseph Frank Sambrook was a British molecular biologist known for his studies of DNA oncoviruses and the molecular biology of normal and cancerous cells.
The Peter MacCallum Cancer Centre, also known as the Peter MacCallum Cancer Institute and commonly abbreviated as Peter Mac, is an Australian oncology research institute, cancer treatment and professional oncologist training centre located in Melbourne, Victoria. The centre is named in honour of Sir Peter MacCallum. Since June 2016, the centre has been located within the Victorian Comprehensive Cancer Centre (VCCC) in Parkville.
Sir Peter MacCallum was a Scottish-born Australian oncologist and the co-founder and eponym of the Peter MacCallum Cancer Centre in Melbourne.
Ian Olver AM is an Australian medical oncologist, cancer researcher and bio-ethicist. He is a former chief executive officer of Cancer Council Australia and a noted authority and media commentator on cancer issues.
Jane Visvader is a scientist specialising in breast cancer research who works for the Walter and Eliza Hall Institute in Melbourne, Australia. She is the joint head of the Breast Cancer Laboratory with Geoff Lindeman.
Michelle Haber is an Australian cancer researcher in the field of childhood cancer research.
Judith Ann Clements is an Australian academic and educator, specializing in Kallikrein proteases in prostate and ovarian cancers. Clements is the scientific director at the Australian Prostate Cancer Research Centre – Queensland and was head of the Cancer Research Program at the Institute of Health and Biomedical Innovation (IHBI) of Queensland University of Technology at the Translational Research Institute (Australia) from 1997–2014. Her biography was published in the Cancer and Metastasis Reviews in 2019
Alicia Yinema Kate Nungarai Oshlack is an Australian bioinformatician and is Co-Head of Computational Biology at the Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia. She is best known for her work developing methods for the analysis of transcriptome data as a measure of gene expression. She has characterized the role of gene expression in human evolution by comparisons of humans, chimpanzees, orangutans, and rhesus macaques, and works collaboratively in data analysis to improve the use of clinical sequencing of RNA samples by RNAseq for human disease diagnosis.
Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that is not associated with cells. ctDNA should not be confused with cell-free DNA (cfDNA), a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin. Because ctDNA may reflect the entire tumor genome, it has gained traction for its potential clinical utility; "liquid biopsies" in the form of blood draws may be taken at various time points to monitor tumor progression throughout the treatment regimen.
A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. Like traditional biopsy, this type of technique is mainly used as a diagnostic and monitoring tool for diseases such as cancer, with the added benefit of being largely non-invasive. Liquid biopsies may also be used to validate the efficiency of a cancer treatment drug by taking multiple samples in the span of a few weeks. The technology may also prove beneficial for patients after treatment to monitor relapse.
Caroline Dive is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, Director of the CRUK Manchester Institute Cancer Biomarker Centre and co-director of the CRUK Lung Cancer Centre of Excellence. She is the current President of The European Association for Cancer Research (EACR).
Naomi Ruth Wray is an Australian statistical geneticist at the University of Queensland, where she is a Professorial Research Fellow at the Institute for Molecular Bioscience and an Affiliate Professor in the Queensland Brain Institute. She is also a National Health and Medical Research Council (NHMRC) Principal Research Fellow and, along with Peter Visscher and Jian Yang, is one of the three executive team members of the NHMRC-funded Program in Complex Trait Genomics. She is also the Michael Days Chair of Psychiatric Genetics at Oxford University. Naomi pioneered the use of polygenic scores in human genetics, and has made significant contributions to both the development of methods and their clinical use.
Elizabeth Ruth Plummer is a Professor of Experimental Cancer Medicine at Newcastle University and an oncologist specialising in treating patients with melanoma. Based in Newcastle, she directs the Sir Bobby Robson Cancer Trials Research Centre, set up by the Sir Bobby Robson Foundation to run early-stage clinical trials.v Plummer and the Newcastle team won a 2010 Translational Cancer Research Prize from Cancer Research UK for work using rucaparib to treat ovarian cancer. Plummer was elected as a fellow of the UK's Academy of Medical Sciences in 2018.
Misty Rayna Jenkins is an Australian scientist known for her research into lymphocytes and cancer treatment.
Helmy Eltoukhy is an American scientist and a businessperson who co-founded startups Avantome and Guardant Health. He is best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. His startups were acquired by Illumina in 2008. Avantome was founded to develop and commercialize semiconductor-based DNA sequencing, during the race for the $1,000 genome. Guardant Health was founded to pioneer non-invasive liquid biopsy approaches for cancer diagnosis, monitoring, personalized medicine treatment, and research.
Professor James D Brenton is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute and Professor of Ovarian Cancer Medicine in the Department of Oncology, University of Cambridge. He is an Honorary Consultant in Medical Oncology at Addenbrooke's Hospital, Cambridge University Hospitals, Ovarian Cancer Domain Lead for the 100,000 Genomes Project by Genomics England, and co-founder and Clinical Advisor to Inivata Ltd, a clinical cancer genomics company.
Carolyn Mary Sue is an Australian physician-scientist, professor and research director. She has been the Executive Director of the Kolling Institute of Medical Research since 2019 and is also Director of Neurogenetics at Royal North Shore Hospital, Director of the Centre of Excellence for Parkinson's Disease and Movement Disorders, and Director of the National Centre for Adult Stem Cell Research. Sue specialises in complex neurogenetic conditions and runs tertiary referral clinics for patients with diseases such as Parkinson's, mitochondrial diseases, and other inherited movement disorders. Her research has identified several previously-unknown mutations that cause neurogenetic disease.
Nitzan Rosenfeld is a professor of Cancer Diagnostics at the University of Cambridge. He is a Senior Group Leader at the Cancer Research UK Cambridge Institute and co-founder of Inivata, a clinical cancer genomics company.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
